KKR Acquires Majority Stake in HealthCare Royalty Partners to Enhance Biopharma Capabilities

KKR has acquired a majority stake in HealthCare Royalty Partners, a biopharma royalty acquisition company, enhancing its capabilities in biopharma royalty and credit investing. The deal adds $3 billion to KKR's assets under management and enables the company to offer a range of financing solutions across the biopharma sector. KKR has a long history of investing in the health care sector, with over $20 billion of equity capital invested since 2004.

KKR & Co. Inc. has acquired a majority stake in HealthCare Royalty Partners, a biopharma royalty acquisition company, significantly enhancing its capabilities in biopharma royalty and credit investing. The deal, announced on July 2, 2025, adds $3 billion to KKR's assets under management and enables the company to offer a range of financing solutions across the biopharma sector [1].

HealthCare Royalty Partners specializes in acquiring and managing royalties from biopharmaceutical products. The acquisition aligns with KKR's long-standing strategy of investing in the health care sector, where it has over $20 billion of equity capital invested since 2004 [2].

The deal underscores KKR's commitment to expanding its biopharma portfolio and leveraging its extensive experience in the sector. By acquiring HealthCare Royalty Partners, KKR aims to provide innovative financing solutions to biopharma companies, helping them to accelerate product development and commercialization.

The acquisition comes at a time when KKR has been actively involved in various strategic initiatives. Just recently, KKR completed a $6.5 billion asset-based finance fundraise, further strengthening its financial position [3]. Additionally, KKR has been involved in several high-profile investments, including the development of a hyperscale data center campus in Texas and the acquisition of Metronet through a joint venture [4].

KKR's recent financial performance has been robust. The company reported $1.18 earnings per share (EPS) for the second quarter of 2025, beating analysts' expectations of $1.14 by $0.04 [5]. The company also increased its quarterly dividend to $0.185 per share, reflecting a 0.5% yield [6].

Institutional investors have shown strong confidence in KKR, with the Public Sector Pension Investment Board increasing its stake by 3.1% in the first quarter, acquiring an additional 5,407 shares [7]. This increase, along with similar moves by other institutional investors, underscores the market's belief in KKR's growth potential.

Looking ahead, KKR's acquisition of HealthCare Royalty Partners is expected to further solidify its position in the biopharma sector and provide investors with a diversified portfolio of investment opportunities. The company's strategic focus on biopharma, coupled with its strong financial performance, positions it well for future growth.

References:
[1] https://au.finance.yahoo.com/quote/KKR.NE/press-releases/
[2] https://www.marketbeat.com/instant-alerts/filing-public-sector-pension-investment-board-purchases-5407-shares-of-kkr-co-inc-nysekkr-2025-08-12/
[3] https://au.finance.yahoo.com/quote/KKR.NE/press-releases/
[4] https://au.finance.yahoo.com/quote/KKR.NE/press-releases/
[5] https://au.finance.yahoo.com/quote/KKR.NE/press-releases/
[6] https://au.finance.yahoo.com/quote/KKR.NE/press-releases/
[7] https://www.marketbeat.com/instant-alerts/filing-public-sector-pension-investment-board-purchases-5407-shares-of-kkr-co-inc-nysekkr-2025-08-12/